sulfonylureas (SUs)

About Topics

Topics include original Beta Cells in Diabetes content, as well as expert-selected resources chosen by our Editorial Board.

Case 5: Graduate Student with Atypical Symptoms

A 25-year-old graduate student originally presented to you with symptoms of a UTI. An urinanalysis showed signs of infection, as well as glycosuria.

Tailoring Clinical Practice Guidelines for Patients with Type 2 Diabetes

Several guidelines emphasize the need to use existing therapeutic options to help patients and providers achieve various treatment goals, including target glycated hemoglobin levels to improve microvascular outcomes among patients with type 2 diabetes.

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations.

Bennett, Wendy L; Maruthur, Nisa M; Singh, Sonal; Segal, Jodi B; Wilson, Lisa M; Chatterjee, Ranee; Marinopoulos, Spyridon S; Puhan, Milo A; Ranasinghe, Padmini; Block, Lauren; Nicholson, Wanda K; Hutfless, Susan; Bass, Eric B; Bolen, Shari
Annals of internal medicine; 2011 May 3;154(9):602-13. PMID: 21403054;
Category: Interventions;

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

Gross, Jorge L; Kramer, Caroline K; Leitão, Cristiane B; Hawkins, Neil; Viana, Luciana V; Schaan, Beatriz D; Pinto, Lana C; Rodrigues, Ticiana C; Azevedo, Mirela J
Annals of internal medicine; 2011 May 17;154(10):672-9. PMID: 21576535;

T2DM and Fatty Liver Disease: Is What’s Good for the Gander Good for the Goose?

Fatty liver disease is the most common cause of chronic liver disease in North America[1] and is becoming one of the top reasons for liver transplantation. Fatty liver causes inflammation that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma.

Do Beta Cells Need Secretory Respite?

Evidence that protecting pancreatic beta cells from chronic overstimulation to maintain glucose homeostasis has led to the concept of “beta cell rest” to preserve or restore beta cell function by temporarily inhibiting insulin secretion.

Beta Cell Pathophysiology and Pharmacotherapy

A leading primary care physician and a world-renowned beta cell researcher discuss how understanding the pathophysiology of beta cells will influence a primary care doctor's choice of drug therapies for their patients. (28:39)

New Concepts, Research and Therapies: A Conversation

Doron Schneider, MD, a leading primary care physician and Jack Leahy, MD, a world-renowned beta cell researcher, discuss the new concepts, current research and therapies. (48:08)

FAQ: How durable are the effects of drugs used to treat type 2 diabetes?

Frequently asked questions for the primary care community, excerpted from a conversation between a leading primary care physician and a world-renowned beta cell researcher. (3:56)

  • Page 1 of 2
  •  
  • Next
|